WO2014178489A1

WO2014178489A1 - Method for treating surface of implant

Info

Publication number: WO2014178489A1
Application number: PCT/KR2013/008525
Authority: WO
Inventors: 하경원; 최규옥
Original assignee: 오스템임플란트 주식회사
Priority date: 2013-05-02
Filing date: 2013-09-24
Publication date: 2014-11-06
Also published as: JP2016522026A; EP2992908A1; CN105339017B; ES2828063T3; EP2992908A4; US10786602B2; EP2992908B1; HUE051263T2; DK2992908T3; JP6383783B2; PT2992908T; KR101404632B1; CN105339017A; US20160058920A1

Abstract

Disclosed is a method for treating the surface of an implant. The disclosed method for treating the surface of an implant comprises the steps of: (coating step) coating a surface treatment composition containing an organic material having a hydrophilic group on the surface of an implant; and (drying step) drying the coated surface treatment composition.

Description

Surface treatment method of implant

Disclosed is a surface treatment method of an implant. More specifically, disclosed is a method for surface treatment of an implant comprising applying a surface treatment composition comprising a hydrophilic group-containing organic material to the surface of the implant.

There are many ways to reduce the failure rate of the dental implant procedure applied to the living body and increase the fixation force with the bone.

A method of mechanically and strongly securing the implant to the bone by designing the implant helically is commonly used.

In addition, in order to increase the surface area of the implant by applying roughness to the surface of the implant through the sandblasting and acid etching method for the strong fixing force of the implant and bone, many implant manufacturers commonly apply It is one of the surface treatment methods.

In addition to the method of fixing the implant surface mechanically and physically strongly with the bone, various methods of coating the implant surface with calcium phosphate, an inorganic component similar to human bone, are used to make the bone better adhere to the implant.

Titanium or titanium alloy used as an implant is contaminated at the same time as air exposure and loses the activity of the surface even if various surface treatment as described above. Surfaces of titanium or titanium alloys react with the surrounding oxygen when exposed to air or water and oxidize continuously (HP Boehm, Acidic and Basic Properties of hydroxylated Metal Oxide Surfaces, Discussions Faraday Society, vol. 52, 1971, pp. 264 -275).

Among the methods used to reduce the failure rate of the implant procedure and to obtain a stable and strong fixation force of the implant and bone, the chemical method includes the hydrophilic characteristics of the implant surface to prevent contamination of the implant surface or immediately after the surface treatment (hereinafter, referred to as `` immediately after surface treatment Hydrophilic properties). In general, the hydrophilicity immediately after surface treatment decreases gradually as the surface of the implant is contaminated by air exposure and undergoes a continuous oxidation reaction, resulting in the hydrophobic nature of the surface. As a method to maintain hydrophilic properties immediately after surface treatment and to prevent surface contamination, US 6,702,855 B1 performs all the processes from the surface treatment stage of the implant to just before the implantation stage under the atmosphere of an inert gas, and the packaging is also water or ion By using a solution, a method of blocking contact between the air and the implant is used. The method of immersing and sealing the implant in the pack containing the physiological solution in an inert gas atmosphere as in the above method can prevent the implant from being exposed to air and contaminate, but the surface of the implant continuously reacts with the water in the physiological solution. Oxidation results in the formation of a new embossed oxide layer on the implant surface, which causes the initial quality of the implant surface immediately after its manufacture and its quality during distribution to vary in terms of surface structure and chemical properties (European Cells and Materials Vol 23. Suppl. 1, 2012, page 25). In addition, the need for airtight packaging can result in complex processes, high processing costs and inconvenient handling.

Korean Patent Application No. 2009-7019196 discloses a method of maintaining the hydrophilicity of an implant surface for a long time, and a method of storing the implant by using a salt-containing aqueous solution and applying a gas-sealed or liquid-sealed package. In particular, the method recommends an aqueous solution of high concentration of inorganic salt of 0.5 M or more in order to maintain the hydrophilicity of the implant surface. However, in the case of sodium chloride (NaCl), which is the most abundant inorganic ions in the body, the concentration is 0.9% by weight and only about 0.15M in terms of molarity. Therefore, it can be predicted by anyone in the relevant industry that an implant to which an aqueous solution of high concentration of inorganic salt of 0.5 M or more is applied may cause an imbalance of inorganic ions in the body, thereby causing toxicity. Therefore, it is not preferable to use an aqueous solution of high concentration inorganic salt of 0.5 M or more for maintaining hydrophilicity.

One embodiment of the present invention provides a surface treatment method of an implant comprising the step of applying a surface treatment composition comprising a hydrophilic group-containing organic material on the surface of the implant.

Another embodiment of the present invention provides a surface treatment method of an implant comprising applying a surface treatment composition comprising a hydrophilic group-containing organic material and an inorganic salt to the surface of the implant.

One aspect of the invention,

Applying a surface treatment composition comprising a hydrophilic group-containing organic material to the surface of the implant (application step); And

It provides a surface treatment method of the implant comprising the step (drying step) of drying the applied surface treatment composition.

The method may further include pretreating the surface of the implant (pretreatment step) before the application step.

The pretreatment step may be performed by at least one of sand blasting, calcium phosphate coating, UV treatment, plasma treatment, acid treatment and base treatment.

The hydrophilic group may include at least one selected from the group consisting of a hydroxyl group (OH), a carboxyl group (COOH), an amino group (NH ₂ ), and a sulfonic acid group (-SO ₃ H).

The organic material may include at least one selected from the group consisting of sugars, proteins, acids, and biological buffers or good's buffers.

The sugars include glucose, cellulose, alkyl cellulose, alkyl hydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid and hyaluronic acid. Salt, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl Chitosan, chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenan, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid ), Polyglucuronic acid, polyguluron It may include at least one selected from the group consisting of acid (polyguluronic acid) and derivatives of the saccharides.

The protein is gelatin, prothrombin, thrombin, fibrinogen, fibrin, fibronectin, heparanase, factor X, factor Xa, factor VII, factor VIIa, factor IX, factor IXa, factor XI, factor XIa, factor XII, factor XIIa, tissue Factor, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin, platelet surface glycoproteins, vasopressin ), Vasopressin analogs, epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet activating factor and peptide It may include at least one selected from the group.

The acid is pyruvic acid (lactic acid), lactic acid (lactic acid), cysteine (cysteine), glutamine (glutamine), tyrosine (tyrosine), leucine (leucine), lysine (lycine), valine (isoline), isoleucine, Threonine, Phenylalanine, Tryptophan, Histidine, Arginine, Glycine, Glycine, Serine, Proline, Glutamic Acid, Aspartic Acid acid), alanine (alanine), methionine (methionine) and asparagine (asparagine) may include at least one selected from the group consisting of.

The biological buffers include MES (2- (N-morpholino) ethanesulfonic acid), ADA (N- (carbamoylmethyl) iminodiacetic acid), PIPES (1,4-piperazindietansulfonic acid), ACES (2 -(Carbamoylmethylamino) ethanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), cholamine chloride, MOPS (3-morpholinopropane-1-sulfonic acid), BES (N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), TES (2-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] Ethanesulfonic acid), HEPES (2- [4- (2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid), DIPSO (3- (N, N-bis [2-hydroxyethyl] amino) -2 Hydroxypropanesulfonic acid), acetamido glycine, TAPSO (3-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] -2-hydroxy Propane-1-sulfonic acid), HEPPSO (N- (2-hydroxyethyl) piperazine-N '-(2-hydroxypropanesulfonic acid), HEPPS (4- (2-hydroxyethyl) -piperazine-1- Propanesulfonic acid), T ricine (N- (2-hydroxy-1,1-bis (hydroxymethyl) ethyl) glycine), glycinamide, Bicine (2-bis (2-hydroxyethyl) amino) acetic acid) and TAPS ( At least one selected from the group consisting of 3-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] propane-1-sulfonic acid).

The concentration of the organic material in the surface treatment composition may be 2,000mM or less.

The surface treatment composition may further include an inorganic salt.

The inorganic salt may include at least one selected from the group consisting of metal chlorides, metal phosphates, metal sulfates, metal carbonates and metal nitrates.

The metal in the inorganic salt may include at least one selected from the group consisting of sodium, calcium, potassium, strontium, manganese and magnesium.

The concentration of the inorganic salt in the surface treatment composition may be 200 mM or less.

The surface treatment composition may be in the form of an aqueous solution.

The implant may comprise titanium or a titanium alloy.

The drying step may be carried out at a temperature of 200 ℃ or less.

The surface treatment method of the implant according to the embodiment of the present invention is simple in processing, low in processing cost and easy to handle, and enables the maintenance of hydrophilic properties in the packaging of the implant by a general packaging.

The surface treatment method of the implant according to another embodiment of the present invention is a method of maintaining hydrophilicity on the surface of the implant, unlike the conventional sealing method is a method that can preserve the hydrophilicity of the surface of the implant without sealing packaging.

1 is a photograph showing the color difference between the implants (Examples 1 to 3) undergoing both pretreatment and post-treatment and the implants (Comparative Example 1) undergoing only pretreatment.

2 is a photograph showing the blood affinity of the implants (Examples 1 to 3) undergoing both pretreatment and post-treatment and the implants (Comparative Example 1) undergoing only pretreatment.

Figure 3 is a photograph showing the surface state of the implant according to the presence of physiological saline in the composition for surface treatment of the implant and glucose concentration.

Figure 4 is a photograph showing the surface state of the implant according to the inclusion of HEPES and / or physiological saline in the surface treatment composition of the implant.

Hereinafter, a method for treating the surface of an implant according to an embodiment of the present invention will be described in detail.

The surface treatment method of an implant according to an embodiment of the present invention is a step (application step) (S10) of applying a surface treatment composition containing a hydrophilic group-containing organic material on the surface of the implant, and drying the coated surface treatment composition It includes a step (drying step) (S20).

The surface of the implant is made hydrophilic by the coating step (S10) and the hydrophilicity is maintained for a long time, and / or the hydrophilicity previously given by the pretreatment step (S1) described later on the surface of the implant can be maintained for a long time. have.

The hydrophilic group-containing organic substance (hereinafter, simply referred to as "organic substance") serves to maintain the surface of the implant to remain hydrophilic until after it remains on the surface of the implant and is placed in the alveolar bone or the like. When the surface of the implant maintains hydrophilicity, the surface becomes high in affinity with the blood so that the entire surface is sufficiently wetted with blood so that new tissue is rapidly formed on the surface, so that the implant is tightly coupled with the surrounding tissue.

The organic material may be an organic material used for blood injection or cell culture.

The protein is gelatin, prothrombin, thrombin, fibrinogen, fibrin, fibronectin, heparanase, factor X, factor Xa, factor VII, factor VIIa, factor IX, factor IXa, factor XI, factor XIa, factor XII, factor XIIa, tissue Factors, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin, platelet surface glycoproteins, vasopressin ), Vasopressin analogs, epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet activating factor and peptide It may include at least one selected from the group.

The acids are pyruvic acid (lactic acid), lactic acid (lactic acid), cysteine (cysteine), glutamine (glutamine), tyrosine (tyrosine), leucine, leucine, lycine, valine, isoleucine, isoleucine, Threonine, Phenylalanine, Tryptophan, Histidine, Arginine, Glycine, Glycine, Serine, Proline, Glutamic Acid, Aspartic Acid acid), alanine (alanine), methionine (methionine) and asparagine (asparagine) may include at least one selected from the group consisting of.

The concentration of the organic material in the surface treatment composition may be 2,000mM or less. Specifically, the concentration of the organic material in the surface treatment composition may be more than 0mM to 2,000mM or less. When the concentration of the organic material in the surface treatment composition is 2,000mM or less, the surface treatment composition may be well dried after being applied to the surface of the implant.

The surface treatment composition may further include an inorganic salt.

The inorganic salt promotes drying of the surface treatment composition in the drying step 20, and after the drying step 20 to dry the entire surface of the implant applied with the surface treatment composition at a uniform rate It serves to prevent the formation of stains on the surface of the implant.

The inorganic salt may be an inorganic salt constituting a physiological solution.

The inorganic salt is sodium chloride, calcium chloride, potassium chloride, strontium chloride, manganese chloride, magnesium chloride, sodium phosphate, calcium phosphate, potassium phosphate, strontium phosphate, manganese phosphate, magnesium phosphate, sodium nitrate, calcium nitrate, potassium nitrate, strontium nitrate, nitrate It may include at least one selected from the group consisting of manganese, magnesium nitrate, sodium carbonate, calcium carbonate, potassium carbonate, strontium carbonate, manganese carbonate, magnesium carbonate, sodium sulfate, calcium sulfate, potassium sulfate, strontium sulfate, manganese sulfate, and magnesium sulfate .

The concentration of the inorganic salt in the surface treatment composition may be 200 mM or less. Specifically, the concentration of the inorganic salt in the surface treatment composition may be more than 0mM to 200 mM or less. If the concentration of the inorganic salt in the surface treatment composition is 200mM or less, even after the surface treatment composition is applied to the surface of the implant may not express cytotoxicity (cytotoxicity).

The surface treatment composition may be in the form of an aqueous solution. In the present specification, the "aqueous solution form" means that at least an organic substance and / or an inorganic salt of the components of the surface treatment composition are present in a dissolved state in water.

As one example, the surface treatment composition may be an aqueous glucose solution having a concentration of 10 ~ 200mM.

As another example, the surface treatment composition may be a HEPES aqueous solution having a concentration of 5 ~ 150mM.

The implant may comprise titanium or a titanium alloy.

The solvent (eg, water) in the surface treatment composition applied to the surface of the implant is removed by the drying step (S20), and a solid material (that is, an organic material and / or an inorganic salt) on the surface of the implant is removed. This precipitates and remains. As a result, an implant having a hydrophilic dried surface can be obtained.

The drying step (S20) may be carried out at a temperature of 200 ℃ or less. Specifically, the drying step (S20) may be carried out at a temperature of -50 ℃ to 200 ℃ or less. When the temperature of the drying step (S20) is carried out at a temperature of 200 ℃ or less, if the surface treatment composition includes an organic material, the oxidation of the organic material may not occur. When the drying step (S20) is carried out by lyophilization (-20 ℃) at a temperature below zero, it is possible to maintain the hydrophilic characteristics of the implant surface

For example, the drying step (S20) may be performed for 20 minutes to 4 hours at a temperature of 15 ~ 70 ℃.

The surface treatment method of the implant may further include a step (pretreatment step) (S1) of pre-treating the surface of the implant before the coating step (S10).

The surface of the implant is hydrophilic by the pretreatment step (S1).

The pretreatment step S1 may be performed by at least one of sandblasting, calcium phosphate coating, UV treatment, plasma treatment, acid treatment and base treatment.

The implant surface-treated by the surface treatment method can maintain a hydrophilic surface from the surface treatment to after the implantation even by a general packaging rather than a closed package.

Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

Example

Examples 1 to 3: Surface pretreatment and posttreatment of implants

First, UV was irradiated to the surface of a titanium implant (self-made) for 1 hour using a UV apparatus (Atek, AH-1700) (this is called "pretreatment"). Thereafter, 10 μl of the surface treatment composition of Table 1 was applied to the surface of the pretreated implant, and the implant applied with the surface treatment composition was dried at 25 ° C. for 20 minutes and then at 60 ° C. for 2 hours ( This is called post-processing).

Table 1

	Example 1	Example 2	Example 3
Surface treatment composition	200 mM aqueous glucose solution prepared by dissolving glucose powder in distilled water	150mM aqueous glucose solution prepared by dissolving glucose powder in 0.9wt% saline solution	100 mM HEPES aqueous solution prepared by dissolving HEPES powder in 0.9wt% saline solution

Comparative Example 1: Surface Pretreatment of Implant

The surface of the implant was pretreated by UV irradiation on the surface of the titanium implant (self-made) for 1 hour using a UV apparatus (Atek, AH-1700). However, the step of applying and drying the surface treatment composition on the surface of the pretreated implant (ie, the post treatment step) was omitted.

Evaluation example

Evaluation Example 1 Color Evaluation of Implant Surface

In Comparative Example 1, the surface photographs of the implants roughly pretreated and the surface photographs of the implants roughly subjected to both pretreatment and posttreatment in Examples 1 to 3 were taken, and the results are shown in FIG. 1.

Referring to FIG. 1, it can be seen that in Examples 1 to 3, the surface of the implant that has undergone both pretreatment and post-treatment is changed to a color different from that of the implant that has undergone only pretreatment in Comparative Examples 1 to 3. From these results, it can be confirmed that in Examples 1 to 3, solid materials (that is, sodium chloride derived from hydrophilic glucose and / or physiological saline) remain on the surface of the implant after both pretreatment and posttreatment.

Evaluation Example 2: Evaluation of Blood Affinity on the Implant Surface

Implants subjected to both pretreatment and post-treatment in Comparative Example 1 and the implants after both pre-treatment and post-treatment in Examples 1 to 3 were immersed in human blood and taken out, and then photographs of the respective implants were taken and the results are shown in FIG. 2. It was.

Referring to FIG. 2, the surface of the implant that has undergone both pretreatment and post-treatment in Examples 1 to 3 is wetted with blood so that a wider area than the surface of the implant that has undergone only pretreatment in Comparative Examples 1 to 3 has affinity with blood. You can see that it is excellent.

Evaluation Example 3: Evaluation of Stain Characteristics of the Composition for Surface Treatment

Photographs showing the surface state of the implant according to the presence of physiological saline and the concentration of glucose in the surface treatment composition of the implant was taken, and the results are shown in FIG. 3. Here, the preparation of the surface treatment composition containing no physiological saline and the surface treatment of the implant was carried out in the same manner as in Example 1 (but the concentration of glucose is changed), the preparation of the surface treatment composition containing physiological saline And the surface treatment of the implant was carried out in the same manner as in Example 2 (but glucose concentration is changed).

Referring to Figure 3, in the case of using a surface treatment composition containing no physiological saline, when the concentration of glucose is low (25 ~ 100mM), the upper and lower surfaces of the implant has a dark color but the middle part has a light color A band-like stain was formed, and when the concentration of glucose was high (200-400 mM), the entire surface of the implant was found to have a dark color without stain.

Referring to FIG. 3, when the surface treatment composition including physiological saline was used, both the low and high glucose concentrations (25-400 mM) were found to have a dark color without staining.

From the above results, it can be seen that physiological saline (ie, sodium chloride) prevents the formation of stains on the surface of the implant after the post-treatment step.

Evaluation Example 3: Evaluation of Drying Properties of Surface Treatment Composition

Photographs showing the surface state of the implant according to the inclusion of HEPES and / or physiological saline in the surface treatment composition of the implant was taken, and the results are shown in FIG. 4. Each titanium implant was pretreated and post-treated in the same manner as in Examples 1-3, except that the following surface treatment compositions were used in each case of FIG.

In Figure 4, "containing only physiological saline" means that 0.9wt% physiological saline was used as the surface treatment composition, "contains only HEPES" means a concentration of 100mM prepared by dissolving HEPES powder in distilled water as a surface treatment composition. Meaning that an aqueous HEPES aqueous solution having a "is used", "containing physiological saline and HEPES" means that the surface treatment composition prepared in Example 3 was used as a surface treatment composition.

Referring to FIG. 4, when only "physiological saline" was used as the surface treatment composition, stains were formed on the surface of the implant. When only "HEPES" was used as the surface treatment composition, the surface of the implant was not dried. Iii) It was found that residues were present. When physiological saline and HEPES were used as the surface treatment composition, no stains were formed on the surface of the implant and no dry residues were present.

From the above results, it can be confirmed that physiological saline (ie, sodium chloride) accelerates the drying of the surface treatment composition applied to the surface of the implant.

Although the present invention has been described with reference to the drawings and embodiments, this is merely illustrative, and those skilled in the art will understand that various modifications and equivalent other embodiments are possible therefrom. Therefore, the true technical protection scope of the present invention will be defined by the technical spirit of the appended claims.

Claims

Applying a surface treatment composition comprising a hydrophilic group-containing organic material to the surface of the implant (application step); And

Surface treatment method of the implant comprising the step (drying step) of drying the coated surface treatment composition.
The method of claim 1,

And pretreating the surface of the implant (pretreatment step) before the coating step.
The method of claim 2,

The pretreatment step is a surface treatment method of the implant is performed by at least one operation of sand blasting, calcium phosphate coating, UV treatment, plasma treatment, acid treatment and base treatment.
The method of claim 1,

The hydrophilic group surface treatment method of the implant comprising at least one selected from the group consisting of hydroxyl group (OH), carboxyl group (COOH), amino group (NH 2 ) and sulfonic acid group (-SO 3 H).
The method of claim 1,

The organic material surface treatment method of the implant comprising at least one selected from the group consisting of saccharides (proteins), proteins (acids) and biological buffers (biological buffer or good's buffer).
The method of claim 5,

The sugars include glucose, cellulose, alkyl cellulose, alkyl hydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid and hyaluronic acid. Salt, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl Chitosan, chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenan, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid ), Polyglucuronic acid, polyguluron Surface treatment method of an implant comprising at least one selected from the group consisting of acid (polyguluronic acid) and the derivative of the saccharide.
The method of claim 5,

The protein is gelatin, prothrombin, thrombin, fibrinogen, fibrin, fibronectin, heparanase, factor X, factor Xa, factor VII, factor VIIa, factor IX, factor IXa, factor XI, factor XIa, factor XII, factor XIIa, tissue Factors, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin, platelet surface glycoproteins, vasopressin ), Vasopressin analogs, epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet activating factor and peptide Surface treatment method of an implant comprising at least one selected from the group.
The method of claim 5,

The acids are pyruvic acid (lactic acid), lactic acid (lactic acid), cysteine (cysteine), glutamine (glutamine), tyrosine (tyrosine), leucine, leucine, lycine, valine, isoleucine, isoleucine, Threonine, Phenylalanine, Tryptophan, Histidine, Arginine, Glycine, Glycine, Serine, Proline, Glutamic Acid, Aspartic Acid acid), alanine (alanine), methionine (methionine) and asparagine (asparagine) at least one selected from the group consisting of surface treatment method of the implant.
The method of claim 5,

The biological buffers include MES (2- (N-morpholino) ethanesulfonic acid), ADA (N- (carbamoylmethyl) iminodiacetic acid), PIPES (1,4-piperazindietansulfonic acid), ACES (2 -(Carbamoylmethylamino) ethanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), cholamine chloride, MOPS (3-morpholinopropane-1-sulfonic acid), BES (N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), TES (2-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] Ethanesulfonic acid), HEPES (2- [4- (2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid), DIPSO (3- (N, N-bis [2-hydroxyethyl] amino) -2 Hydroxypropanesulfonic acid), acetamido glycine, TAPSO (3-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] -2-hydroxy Propane-1-sulfonic acid), HEPPSO (N- (2-hydroxyethyl) piperazine-N '-(2-hydroxypropanesulfonic acid), HEPPS (4- (2-hydroxyethyl) -piperazine-1- Propanesulfonic acid), T ricine (N- (2-hydroxy-1,1-bis (hydroxymethyl) ethyl) glycine), glycinamide, Bicine (2-bis (2-hydroxyethyl) amino) acetic acid) and TAPS ( A method of surface treatment of an implant comprising at least one selected from the group consisting of 3-[[1,3-dihydroxy-2- (hydroxymethyl) propan-2-yl] amino] propane-1-sulfonic acid).
The method of claim 1,

The concentration of the organic matter in the surface treatment composition is a surface treatment method of the implant is 2,000mM or less.
The method of claim 1,

The surface treatment composition is a surface treatment method of an implant further comprising an inorganic salt.
The method of claim 11,

And said inorganic salt comprises at least one selected from the group consisting of metal chlorides, metal phosphates, metal sulfates, metal carbonates and metal nitrates.
The method of claim 12,

Metal in the inorganic salt is a surface treatment method of the implant comprising at least one selected from the group consisting of sodium, calcium, potassium, strontium, manganese and magnesium.
The method of claim 1,

The concentration of the inorganic salt in the surface treatment composition is 200 mM or less surface treatment method of the implant.
The method of claim 1,

The surface treatment composition is a surface treatment method of the implant in the form of an aqueous solution.
The method of claim 1,

The implant is a surface treatment method of an implant containing titanium or titanium alloy.
The method of claim 1,

The drying step is a surface treatment method of the implant is carried out at a temperature of 200 ℃ or less.